Nanometer delivery system for targeted regulation of CAR-T cells and application of nanometer delivery system
By targeting the nanodelivery system that regulates CAR-T cells, nanotechnology regulates CAR-T cell activity and microenvironment in tumor sites, the infiltration and activation of CAR-T cells in the treatment of prostate cancer is solved and the therapeutic effect is improved And reduce side effects, promoting the advancement of nanomedicine and immunotherapy.
Patent Information
- Application Number
- CN202411270244.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-06
AI Technical Summary
CAR-T cell therapy has limited anti-tumor effects on solid tumors, especially in targeted treatment of prostate cancer, the infiltration, proliferation and activation of CAR-T cells in the tumor microenvironment are inhibited, resulting in poor efficacy.
Develop a nanodelivery system targeting the regulation of CAR-T cells, using nanotechnology to achieve precise regulation of CAR-T cell activity and tumor microenvironment through drug-laden DLNP and N3 CAR-T cells, including the use of activation or Drugs that inhibit CAR-T cell activity and drugs that improve the tumor microenvironment, such as IL15, dasatinib hydrochloride and collagenase I, achieve efficient targeting through bioorthogonal reactions.
It significantly improves the killing ability of CAR-T cells to tumor cells, reduces the risk of cytokine storms, improves the tumor microenvironment, improves the treatment safety and efficacy, and promotes the combination of nanomedicine and immunotherapy.
Smart Images

Figure CN119074664A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of nanomedicine and tumor treatment, and in particular relates to a nano delivery system for targeted regulation of CAR-T cells and its application. Background Art
[0002] Prostate cancer is an insidious disease, and most patients are already in the advanced stage when they are discovered. With clinical recurrence and disease progression, it turns into castration-resistant prostate cancer (CRPC). Due to the lack of specific drugs and treatments that can effectively control the development of CRPC, radiotherapy and chemotherapy have long been the first choice for CRPC treatment. However, due to their poor tumor selectivity and large adverse reactions, the efficacy is not satisfactory, resulting in tumor progression and eventual death in most patients. Therefore, various new targeted treatment methods have been explored clinically to improve the treatment effect of CRPC.
[0003] Chimeric antigen receptor T (CAR-T) cell therapy is one of the most promising tumor targeted immunotherapy methods and has achieved good results in the treatment of hematological malignancies and non-Hodgkin's lymphoma. The FDA has approved a number of CAR-T treatments for the official market for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Currently, more than a thousand CAR-T experiments have entered clinical research worldwide. The unprecedented success of CAR-T therapy has provided ideas for the targeted treatment of advanced prostate cancer. Currently, more than ten CAR-T treatment studies for prostate cancer have been carried out in the clinical trial stage. CAR-T therapy has become the hope for targeted treatment of advanced prostate cancer. However, the anti-tumor effect of CAR-T cell therapy on solid tumors remains to be confirmed. The complex tumor microenvironment (TME) of solid tumors is the main challenge of CAR-T cell immunotherapy. TME prevents sufficient cancer-killing immune cells from entering the tumor area and inhibits the activation of tumor-infiltrating lymphocytes (TILs), causing TIL exhaustion, in which the tumor killing ability is greatly reduced.
[0004] Therefore, CAR-T cell therapy urgently needs to address the problems of CAR-T cell infiltration, proliferation, and activation in solid tumors, especially for CAR-T cell therapy targeting prostate cancer. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a nano-delivery system for targeted regulation of CAR-T cells and its application.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a nano-delivery system for targeted regulation of CAR-T cells, wherein the nano-delivery system is a drug-loaded DLNP and N3 CAR-T cells;
[0008] The preparation method of the drug-loaded DLNP comprises the following steps:
[0009] Dissolve lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO in an organic solvent, add a buffer solution containing a drug after the organic phase forms a thin film, heat and stir, and perform ultrasonic homogenization, and then ultrafilter and take the upper layer of liquid to obtain DLNPs loaded with the drug; the drug is a drug that regulates the activity of CAR-T cells or a drug that regulates the tumor microenvironment of CAR-T cells;
[0010] The preparation method of N3 PSMACAR-T cells comprises the following steps:
[0011] The activated T cells were transfected with a lentivirus containing a CAR vector and cultured to obtain CAR-T cells, and Ac4GalNAz was added for co-culture to obtain N3 CAR-T cells.
[0012] Preferably, the mass ratio of lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO is (45-55):(10-12):(6-7):(7-7.5).
[0013] Preferably, the drug that regulates the activity of CAR-T cells includes a drug that activates the activity of CAR-T cells or a drug that inhibits the activity of CAR-T cells; the drug that regulates the tumor microenvironment of CAR-T cells is a drug that improves the tumor microenvironment of CAR-T cells.
[0014] Preferably, the drug for activating the activity of CAR-T cells includes IL15, the drug for inhibiting the activity of CAR-T cells includes dasatinib hydrochloride; and the drug for improving the tumor microenvironment of CAR-T cells is collagenase I.
[0015] Preferably, the organic solvent includes chloroform, and the buffer solution includes PBS solution.
[0016] Preferably, the preparation of the activated T cells comprises the following steps: obtaining lymphocytes from the venous blood of healthy persons, adding anti-CD3 / CD28 magnetic beads to activate the T cells, and obtaining the activated T cells.
[0017] Preferably, the concentration of Ac4GalNAz is 45-55 μM, and the co-culture time is 40-50 h.
[0018] Preferably, the CAR-T cells are PSMA CAR-T cells, and the lentivirus containing the CAR vector is Lenti-GFP / PSMA-CAR virus.
[0019] Preferably, the mass ratio of the lecithin to the drug is (45-55):(0.8-1.0).
[0020] The present invention provides an application of the nano delivery system, wherein the application is one or more of the following:
[0021] (1) Application of the nano-delivery system in the preparation of drugs for treating tumors;
[0022] (2) Application of the nano-delivery system in the preparation of targeted tumor therapy drugs;
[0023] (3) Application of the nano-delivery system in the preparation of drugs for reducing cytokine storm caused by CAR-T cells.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention provides a nano-delivery system for targeted regulation of CAR-T cells and its application. The present invention realizes the precise targeting of CAR-T cells at the tumor site by nanotechnology for the first time, and regulates the activity of CAR-T cells or regulates the tumor microenvironment of CAR-T cells through drug-encapsulated DLNP, thereby solving the problems of cytokine storm caused by exhaustion, insufficient killing activity or excessive CAR-T cells of CAR-T cells. Therefore, the nano-delivery system for targeted regulation of CAR-T cells of the present invention can significantly target and kill tumor cells by changing the type of encapsulated drugs, solve the problem of cytokine storm caused by excessive CAR-T cells, improve the safety of CAR-T cells killing tumors, and improve the tumor microenvironment. Therefore, the present invention further promotes the combination and development of the clinical application of nanomedicine and immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 A is the particle size distribution diagram of DLNP, and B is the transmission electron microscopy image of DLNP;
[0027] Figure 2 A is the particle size distribution diagram of rhodamine DLNP, and B is the transmission electron microscopy image of rhodamine DLNP;
[0028] Figure 3 This is a graph of the transfection efficiency of N3 PSMACAR-T cells;
[0029] Figure 4Flow cytometry was used to measure the modification results of azide groups on the surface of N3 PSMACAR-T cells;
[0030] Figure 5 This is a confocal microscopy image of the in vitro binding of rhodamine DLNPs to N3 PSMACAR-T;
[0031] Figure 6 Confocal microscopy images of the in vivo binding of rhodamine DLNPs to N3 PSMACAR-T;
[0032] Figure 7 A is the particle size distribution diagram of IL15-encapsulated DLNPs, and B is the transmission electron microscopy image of IL15DLNPs;
[0033] Figure 8 The in vitro killing effect of IL-15DLNP combined with N3 PSMACAR-T on PSMA(+) PC3 cells;
[0034] Fig. 9 A shows the effect of N3 PSMACAR-T combined with IL15 DLNP on the tumor volume of mice within 18 days, B shows the effect of N3 PSMACAR-T combined with IL15 DLNP on the tumor weight of mice after 18 days, and C shows the immunohistochemical detection of CD3+T cell infiltration in the tumor tissue of mice after 18 days by N3 PSMACAR-T combined with IL15 DLNP.
[0035] Fig.10 A is a particle size distribution diagram of DLNPs loaded with dasatinib hydrochloride, and B is a transmission electron microscopy image of DLNPs loaded with dasatinib hydrochloride;
[0036] Fig.11 A shows the change of tumor volume in mice treated with N3 PSMACAR-T combined with dasatinib hydrochloride DLNP within 14 days, and B shows the amount of IFN-γ in the serum of mice treated with N3 PSMACAR-T combined with IL15-encapsulated DLNP after 14 days.
[0037] Fig.12 A is the particle size distribution diagram of collagenase Ⅰ DLNP, and B is the transmission electron microscopy image of collagenase Ⅰ DLNP;
[0038] Fig.13A shows the effect of N3 PSMACAR-T combined with collagenase Ⅰ DLNP on the change of tumor volume in mice within 18 days, B shows the effect of N3 PSMACAR-T combined with collagenase Ⅰ DLNP on the tumor weight in mice after 18 days, C shows the immunohistochemistry of type I collagen in tumor tissue of mice after 18 days of treatment with N3 PSMACAR-T combined with collagenase Ⅰ DLNP, and D shows the infiltration of CD3+T cells in tumor tissue of mice after 18 days of treatment with N3 PSMACAR-T combined with collagenase Ⅰ DLNP. DETAILED DESCRIPTION
[0039] The present invention provides a nano-delivery system for targeted regulation of CAR-T cells, wherein the nano-delivery system is a drug-loaded DLNP and N3 CAR-T cells;
[0040] The preparation method of the drug-loaded DLNP comprises the following steps:
[0041] Dissolve lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO in an organic solvent, add a buffer solution containing a drug after the organic phase forms a thin film, heat and stir, and perform ultrasonic homogenization, and then ultrafilter and take the upper layer of liquid to obtain DLNPs loaded with the drug; the drug is a drug that regulates the activity of CAR-T cells or a drug that regulates the tumor microenvironment of CAR-T cells;
[0042] The preparation method of N3 PSMACAR-T cells comprises the following steps:
[0043] The activated T cells were transfected with a lentivirus containing a CAR vector and cultured to obtain CAR-T cells, and Ac4GalNAz was added for co-culture to obtain N3 CAR-T cells.
[0044] In the present invention, the drug-encapsulated DLNP is a DBCO-labeled drug-encapsulated liposome. The N3CAR-T cell is an azide (N3)-labeled CAR-T cell. The above-mentioned DBCO-labeled drug-encapsulated liposome and the azide (N3)-labeled CAR-T cell are combined by DBCO and N3 due to bioorthogonal reaction and have efficient targeting. At the same time, the present invention regulates the activity of CAR-T cells by encapsulated drugs, improves the tumor microenvironment of CAR-T cells, and thus realizes remote regulation of CAR-T cell activity. The drug for regulating the activity of CAR-T cells includes a drug that activates the activity of CAR-T cells or a drug that inhibits the activity of CAR-T cells; the drug for regulating the tumor microenvironment of CAR-T cells is a drug that improves the tumor microenvironment of CAR-T cells. As one embodiment, the drug for activating the activity of CAR-T cells includes IL15, and the drug for inhibiting the activity of CAR-T cells includes dasatinib hydrochloride; the drug for improving the tumor microenvironment of CAR-T cells is collagenase I.
[0045] In the present invention, the preparation of drug-encapsulated DLNPs includes dissolving lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO in an organic solvent, adding a buffer solution containing the drug after the organic phase forms a thin film, heating and stirring, ultrasonic homogenization, ultrafiltration, and taking the upper liquid to obtain drug-encapsulated DLNPs. The mass ratio of lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO is preferably (45-55): (10-12): (6-7): (7-7.5), further preferably (48-52): (10.5-11.5): (6.2-6.8): (7.1-7.4), and more preferably 50:11:6.6:7.2. The mass ratio of lecithin to the drug is preferably (45-55): (0.8-1.0), and further preferably 50:0.9. The organic solvent includes chloroform, the buffer solution includes PBS solution, and the volume mass ratio of the organic solvent to lecithin is preferably 2-4 mL:45-55 mg, more preferably 3 mL:48-52 mg, and more preferably 3 mL:50 mg. The heating temperature is 35-40 ° C, more preferably 37 ° C, and the heating time is 25-35 min, more preferably 30 min. The ultrasonic time is preferably 4-6 min, and more preferably 5 min. The number of ultrafiltration is 2-4 times, the time of each ultrafiltration is 5-15 min, and the speed of ultrafiltration is 4500-5500 r / min. After ultrafiltration, the upper layer liquid obtained by ultrafiltration is filtered through a 100 nm filter membrane to obtain drug-loaded DLNP.
[0046] In the present invention, the preparation method of N3 PSMACAR-T cells includes: after the activated T cells are transfected with a lentivirus containing a CAR vector, they are cultured to obtain CAR-T cells, and Ac4GalNAz is added for co-culture to obtain N3 CAR-T cells. The preparation of the activated T cells includes the following steps: obtaining lymphocytes from the venous blood of a healthy person, adding anti-CD3 / CD28 magnetic beads to activate the T cells, and obtaining. The method of obtaining lymphocytes in the present invention can be selected as obtaining lymphocytes using human peripheral blood lymphocyte separation fluid, and after obtaining lymphocytes, resuspending and mixing in X-VIVO medium containing 10ng / mL IL-2, adding anti-CD3 / CD28 magnetic beads to activate T cells, and placing them in a 37°C, 5% CO2 incubator for 48h to obtain activated T cells. After obtaining the activated T cells, they are transfected with a lentivirus containing a CAR vector and cultured to obtain CAR-T cells. The culture method is to culture them in X-VIVO medium containing 10ng / mL IL-2 for 3 days. After obtaining CAR-T cells, Ac4GalNAz is added for co-culture to obtain N3 CAR-T cells. The concentration of Ac4GalNAz is preferably 45-55 μM, more preferably 48-52 μM, and more preferably 50 μM. The co-culture time is preferably 40-50 h, more preferably 42-49 h, and more preferably 48 h.
[0047] In the present invention, the CAR-T cells are PSMA C-T cells, and the lentivirus containing the CAR vector is Lenti-GFP / PSMA-CAR virus.
[0048] The present invention provides an application of the nano delivery system, wherein the application is one or more of the following:
[0049] (1) Application of the nano-delivery system in the preparation of drugs for treating tumors;
[0050] (2) Application of the nano-delivery system in the preparation of targeted tumor therapy drugs;
[0051] (3) Application of the nano-delivery system in the preparation of drugs for reducing cytokine storm caused by CAR-T cells.
[0052] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.
[0053] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0054] In the following examples, the DSPE-PEG2000 was purchased from Pengshuo Biotechnology with the product number PS2-2k; the DSPE-PEG2000-DBCO was purchased from Pengshuo Biotechnology with the product number PS2-E1DB-2k.
[0055] Example 1 Preparation of bioorthogonal DLNPs
[0056] 50 mg of lecithin, 11 mg of cholesterol, 6.6 mg of DSPE-PEG2000 and 7.2 mg of DSPE-PEG2000-DBCO were dissolved in 3 mL of chloroform, vortexed to completely dissolve, and evaporated under reduced pressure for 30 min using a vacuum rotary evaporator at 40°C to remove chloroform. The organic phase of the lipid component formed a thin film at the bottom of the round-bottom flask. 3 mL of PBS solution was added and stirred for 30 min in a 37°C water bath; probe ultrasound (frequency 20 khz, 20% power) was used for 5 min under an ice bath; a 30 kD ultrafiltration tube was used for ultrafiltration at a speed of 5000 r / min for 10 minutes each time, and the free drug was removed by ultrafiltration three times using a 30 kD ultrafiltration tube, and the upper layer of liquid was collected. The upper layer of liquid was extruded 10 times through a 100 nm filter membrane using an Avanti liposome extruder to finally obtain the product DLNP.
[0057] The particle size distribution is measured by Malvern particle size analyzer. Figure 1 As shown in A in the figure, its morphology was observed by transmission electron microscopy. Figure 1 As shown in B.
[0058] Figure 1 The results show that the DLNPs prepared in the present invention are spherical and have an average particle size of 108 nm.
[0059] Example 2 In vitro binding of DLNPs to N3 PSMACAR-T
[0060] (1) Preparation of Rhodamine Bioorthogonal DLNPs
[0061] 50 mg of lecithin, 11 mg of cholesterol, 6.6 mg of DSPE-PEG2000 and 7.2 mg of DSPE-PEG2000-DBCO were dissolved in 3 mL of chloroform, vortexed to completely dissolve, and evaporated under reduced pressure for 30 min using a vacuum rotary evaporator at 40°C to remove chloroform. The organic phase formed a thin film at the bottom of the round-bottom flask, and 3 mL of 2 mg / mL rhodamine PBS solution was added. The mixture was stirred for 30 min in a 37°C water bath. The mixture was treated with a probe for 5 min in an ice bath. A 30 kD ultrafiltration tube was used for ultrafiltration at a speed of 5000 r / min for 10 min each time. The free drug was removed by ultrafiltration three times using a 30 kD ultrafiltration tube, and the upper layer of liquid was collected. The upper layer of liquid was extruded 10 times through a 100 nm filter membrane using an Avanti liposome extruder to obtain the product rhodamine DLNP.
[0062] The particle size distribution is measured by Malvern particle size analyzer. Figure 2 As shown in A, its morphology was observed by transmission electron microscopy. Figure 2 As shown in B.
[0063] Figure 2 The results showed that rhodamine DLNPs were spherical with an average particle size of 121.4 nm.
[0064] (2) Preparation of N3 PSMACAR-T
[0065] 15 mL of venous blood was obtained from healthy volunteers, and lymphocytes were obtained using human peripheral blood lymphocyte separation fluid. The cells were resuspended and mixed in X-VIVO medium containing 10 ng / mL IL-2, and anti-CD3 / CD28 magnetic beads were added to activate T cells. The cells were cultured in a 37°C, 5% CO2 incubator for 48 h to obtain activated T cells. The activated T cells were transfected with Lenti-GFP / PSMA-CAR lentivirus (purchased from Shanghai JiKai Gene Chemistry Technology Co., Ltd., catalog number GORL0292787), and then cultured in X-VIVO medium containing 10 ng / mL IL-2 for 3 days to obtain PSMACAR-T cells. Ac4GalNAz was added to the X-VIVO medium, and the Ac4GalNAz concentration was controlled to 50 μM for co-culture for 48 h to obtain N3 PSMACAR-T cells.
[0066] The percentage of PSMACAR-positive T cells in N3 PSMACAR-T cells (denoted as N3 CAR-T cells) was determined by flow cytometry analysis, and the percentage of PSMACAR-positive T cells in PSMACAR-T cells (denoted as CAR-T cells) and T cells (denoted as T cells) was also detected.
[0067] like Figure 3 As shown, 62.1% of PSMACAR-T cells or N3 PSMACAR-T cells expressed GFP protein, indicating that PSMACAR-T was successfully prepared.
[0068] To identify the modification of azide groups on the cell surface, flow cytometry was performed using DBCO-Cy5 staining to measure the N3 groups in N3 PSMACAR-T cells.
[0069] like Figure 4 As shown, 98% of N3 PSMA CAR-T cells expressed the N3 group, indicating that the preparation of N3 PSMA CAR-T cells was successful.
[0070] (3) In vitro binding assay between DLNP and N3 PSMACAR-T
[0071] Take N3 PSMACAR-T cells or PSMACAR-T cells prepared in step (2) of this example, and 6 / mLN3PSMACAR-T cells or PSMACAR-T cells were added with 30μL of rhodamine DLNPs prepared in (1) and incubated for 30min. The supernatant was discarded by centrifugation, and the cells were washed with PBS three times. After resuspending in 1mL PBS, the cells were added to a confocal dish and observed using a confocal laser scanning microscope.
[0072] like Figure 5 As shown, the green fluorescence is GFP expressed by CAR-T cells, and the red fluorescence is rhodamine DLNP. It can be observed from the Merge diagram that rhodamine DLNP is basically attached to the surface of N3 PSMACAR-T, while the red fluorescence on the surface of PSMACAR-T cells in the control group is significantly less than that of N3 PSMACAR-T. The results show that N3 PSMACAR-T and DLNP are combined together through the bioorthogonal reaction of N3 and DBCO.
[0073] Example 3 Binding of DLNPs to N3 PSMACAR-T in PSMA(+) PC3 tumor-bearing mice
[0074] (1) Establishment of PSMA(+)PC3 subcutaneous transplanted tumor mouse model: Take logarithmically growing PSMA(+)PC3 cells, digest with trypsin, resuspend in culture medium and collect cells, adjust cell density with PBS solution for later use; select 6-8 week old male NSG mice to establish PSMA(+)PC3 tumor-bearing mouse model. Each NSG mouse is subcutaneously injected with 3×10 6 / mL PSMA(+) PC3 cell suspension 0.1mL.
[0075] (2) In vitro binding assay between DLNP and N3 PSMACAR-T
[0076] The subcutaneous tumor of the tumor-bearing mouse model to be established reaches 50 mm 3 Then, mice were intravenously injected with 5×10 N3 PSMACAR-T cells prepared in step (2) of Example 2. 6 / mL, and two days later, 200 μL of rhodamine DLNP prepared in step (1) of Example 2 was intravenously injected; the mice were euthanized at 2h, 6h, 12h, 24h, 48h, and 72h after the injection of rhodamine DLNP. The tumor was removed, frozen sections were made, immersed in 4% tissue cell fixative for 20min, washed 3 times with PBS, stained with DAPI dye for 3 minutes, washed 3 times with PBS, sealed with anti-fluorescence quenching sealing agent, and observed with a confocal laser scanning microscope.
[0077] like Figure 6 As shown in the figure, over time, the GFP signal at the edge of the tumor gradually increased, indicating that the number of N3PSMACAR-T cells in the tumor tissue continued to increase and showed a trend of infiltrating into the tumor. It is worth noting that the red rhodamine signal and the GFP signal showed a good co-localization phenomenon in the tumor tissue, and as the GFP signal increased, the rhodamine signal also increased. Especially after 72 hours of injection, a large number of rhodamine signals can be observed to be tightly gathered around the N3PSMACAR-T cells, which fully proves that DLNP has efficient targeting of N3 PSMACAR-T cells due to bioorthogonal reaction.
[0078] Example 4 IL-15 DLNPs encapsulated enhance the killing of PSMA(+) PC3 cells by N3 PSMACAR-T in vitro
[0079] (1) Preparation of IL15-loaded DLNPs
[0080] 50 mg of lecithin, 11 mg of cholesterol, 6.6 mg of DSPE-PEG2000 and 7.2 mg of DSPE-PEG2000-DBCO were dissolved in 3 mL of chloroform, vortexed to completely dissolve, and evaporated under reduced pressure using a vacuum rotary evaporator at 40°C to remove chloroform. After the organic phase formed a thin film at the bottom of the round-bottom flask, 3 mL of 300 μg / mL IL15 PBS solution was added, and stirred for 30 min in a 37°C water bath. After the film was completely hydrated, the liposomes were treated with a probe ultrasound for 5 min in an ice bath. Ultrafiltration was performed at a speed of 5000 r / min for 10 min each time, and ultrafiltration was performed three times using a 30kD ultrafiltration tube to remove free drugs. The upper layer of liquid was collected, and the upper layer of liquid was extruded 10 times through a 100 nm filter membrane using an Avanti liposome extruder to obtain the product IL15 DLNP.
[0081] The particle size distribution of IL15-encapsulated DLNPs was measured by Malvern particle size analyzer. Figure 7 As shown in A in the figure, its morphology was observed by transmission electron microscopy. Figure 7 As shown in B.
[0082] Figure 7 The results showed that the IL15-loaded DLNPs prepared in this example were spherical with an average particle size of 118.6 nm.
[0083] (2) In vitro killing of PSMA(+) PC3 cells by IL-15DLNP combined with N3 PSMACAR-T
[0084] The experiment was divided into N3 CAR-T+IL-15DLNP group and PSMACAR-T group. The experimental method was as follows: first, about 3000 PSMA(+)PC3 cells / well were inoculated in a 96-well plate and incubated in cell culture medium for 24 hours. N3 PSMACAR-T cells were prepared according to the method of step (2) of Example 2. N3 PSMACAR-T cells with different effector-target ratios (2:1 and 5:1) were co-incubated with PSMA(+)PC3 cells for 24 hours and then divided into two groups. One group of N3 PSMACAR-T group was simultaneously treated with 30μL of IL15 DLNP for 24 hours, while the other group of N3 PSMACAR-T group was treated with PBS control for 24 hours. The killing ability of CAR-T cells in different groups was detected by lactate dehydrogenase (LDH) release experiment. Killing ability = (absorbance of treated sample - absorbance of sample control well) ÷ (absorbance of maximum enzyme activity of cells - absorbance of sample control well) × 100%. The results are as follows: Figure 8 shown.
[0085] Figure 8The results showed that IL-15DLNP enhanced the in vitro killing of PSMA(+)PC3 cells by N3 PSMACAR-T. When the effector-target ratio was 5:1, IL-15DLNP combined with N3 PSMACAR-T killed 81.58% of PSMA(+)PC3 cells, while N3 PSMACAR-T without IL15 DLNP killed 71.98% of PSMA(+)PC3 cells. When the effector-target ratio was 2:1, the killing abilities were 48.12% and 37.95%, respectively, indicating that IL-15DLNP enhanced the tumor killing ability of N3 PSMACAR-T.
[0086] Example 5 IL-15DLNP and N3 PSMACAR-T enhance the therapeutic effect of PSMACAR-T in PSMA(+) PC3 tumor-bearing mice
[0087] (S1) Take logarithmically growing PSMA(+) PC3 cells, digest them with trypsin, resuspend them in culture medium, and adjust the cell density with sterile phosphate buffered saline (PBS) for later use;
[0088] (S2) 6-8 week old male NSG mice were selected to establish PSMA(+) PC3 tumor-bearing mouse model. Each NSG mouse was subcutaneously injected with 5×10 6 / mL PSMA(+) PC3 cell suspension 0.1mL;
[0089] (S3) PSMA CAR-T cells and N3 PSMA CAR-T cells were prepared according to the method of step (2) of Example 2, and the subcutaneous tumor of the tumor-bearing mouse model established in step (S2) reached 50 mm. 3 Afterwards, the mice were randomly divided into 4 groups, namely group 1, group 2, group 3, and group 4, which were respectively named Control group, CAR-T group, CAR-T+IL-15DLNP group, and N3 CAR-T+IL-15DLNP group. Group 1 was intravenously injected with 100 μL PBS solution; Group 2 was intravenously injected with 5×10 6 PSMACAR-T cells; 5×10 6 PSMACAR-T cells were injected twice intravenously, 2 days after the injection of PSMACAR-T cells, and 200 μL of IL15-loaded DLNP prepared in Example 4 was injected intravenously. 5×10 6 N3PSMACAR-T cells were injected, and 200 μL of IL15-loaded DLNPs prepared in Example 4 were intravenously injected twice, 2 days and 4 days after the injection of N3PSMACAR-T cells.
[0090] (S4) The tumor size was measured every 2 days. The tumor volume was obtained by measuring the length and width of the tumor with a vernier caliper. On day 18, the mice were euthanized. The tumor weight of the mice was weighed. After weighing the tumor weight of the mice, sections were made and immunohistochemistry was performed to detect the infiltration of CD3+T cells in the tumor tissue.
[0091] from Fig. 9 It can be seen that the tumor of the tumor-bearing mice in group 1 injected with PBS by the tail vein grew rapidly within 18 days; the tumor-bearing mice injected with PSMACAR-T by the tail vein had only a small inhibitory effect on tumor growth; the tumor-bearing mice injected with N3PSMACAR-T by the tail vein and treated with IL15 DLNPs, because DLNPs have the function of actively targeting N3-labeled PSMACAR-T, the growth of tumors was significantly inhibited, and the number of T cells infiltrating the tumors was also significantly increased. The above experimental results show that the present invention has successfully prepared a nano-delivery system that uses bio-orthogonal in vivo targeted regulation of PSMACAR-T cells, and when the system uses IL15 DLNPs to target and regulate PSMACAR-T cells, it can achieve significant inhibition of tumor growth.
[0092] Example 6 The therapeutic effect of dasatinib hydrochloride-loaded DLNP and N3 PSMACAR-T on inhibiting CAR-T in PSMA(+) PC3 tumor-bearing mice
[0093] (A1) Preparation of DLNPs loaded with dasatinib hydrochloride
[0094] 50 mg of lecithin, 11 mg of cholesterol, 6.6 mg of DSPE-PEG2000 and 7.2 mg of DSPE-PEG2000-DBCO were dissolved in 3 mL of chloroform, vortexed to completely dissolve, and evaporated under reduced pressure using a vacuum rotary evaporator at 40°C to remove chloroform. After the organic phase formed a thin film at the bottom of the round-bottom flask, 3 mL of 1.5 mg / mL dasatinib hydrochloride PBS solution was added, and stirred for 30 minutes under 37°C water bath heating conditions; after the film was completely hydrated, the liposomes were treated with a probe ultrasound for 5 minutes under an ice bath; a 30 kd ultrafiltration tube was used for ultrafiltration at a speed of 5000 r / min for 10 minutes, and ultrafiltration was performed three times to remove free drugs, and the upper layer liquid was collected. The upper layer liquid was extruded 10 times through a 100 nm filter membrane using an Avanti liposome extruder to finally obtain the product entrapped dasatinib hydrochloride DLNP.
[0095] The particle size distribution is measured by Malvern particle size analyzer. Fig.10 As shown in A in the figure, its morphology was observed by transmission electron microscopy. Fig.10 As shown in B.
[0096] Fig.10 The results showed that the dasatinib hydrochloride-loaded DLNPs prepared in this example were spherical with an average particle size of 172.1 nm.
[0097] (A2) Logarithmically growing PSMA(+) PC3 cells were obtained, digested with trypsin, and resuspended in culture medium to collect the cells. The cell density was adjusted with sterile phosphate buffered saline (PBS) for later use;
[0098] (A3) 6-8 week old male NSG mice were selected to establish PSMA(+) PC3 tumor-bearing mouse model. Each NSG mouse was subcutaneously injected with (A2) to obtain a concentration of 5×10 6 / mL PSMA(+) PC3 cell suspension 0.1mL;
[0099] (A4) PSMA CAR-T cells and N3 PSMA CAR-T cells were prepared according to the method of step (2) in Example 2. When the subcutaneous tumor of the tumor-bearing mouse model established in (A3) reached 50 mm 3 Afterwards, the mice were randomly divided into 4 groups, namely group 1, group 2, group 3, and group 4, which were respectively named Control group, CAR-T group, CAR-T+Dasatinib DLNP group, and N3 CAR-T+Dasatinib DLNP group. Group 1 was intravenously injected with 100 μL PBS solution; Group 2 was intravenously injected with 7×10 6 PSMACAR-T cells; 7×10 6 PSMACAR-T cells were injected intravenously once a day on the 2nd to 4th day after the injection of PSMACAR-T. The four groups were injected intravenously with 7×10 6 N3 PSMACAR-T cells were injected, and the dasatinib hydrochloride-loaded DLNP prepared in this example was intravenously injected once a day on the 2nd to 4th day after the injection of N3 PSMACAR-T cells.
[0100] (A4) The tumor size was measured every 2 days. The tumor volume was obtained by measuring the length and width of the tumor with a vernier caliper. The mice were euthanized on day 14. The tumor weight of the mice was weighed, and the mouse serum was obtained to detect the amount of cytokine IFN-γ in the serum by ELISA.
[0101] from Fig.11As can be seen from A, the tumors of the tumor-bearing mice in group 1 that were injected with PBS through the tail vein grew rapidly within 14 days; the tumor-bearing mice that were injected with PSMACAR-T through the tail vein had a certain inhibitory effect on tumor growth; the tumor-bearing mice that were injected with PSMACAR-T through the tail vein and then treated with dasatinib hydrochloride-encapsulated DLNPs, the dasatinib hydrochloride-encapsulated DLNPs initially inhibited the action of PSMACAR-T cells, but its half-life was very short, and the PSMACAR-T cells recovered and continued to inhibit the tumor. The tumor-bearing mice that were injected with N3 PSMACAR-T through the tail vein and then treated with dasatinib hydrochloride-encapsulated DLNPs, because DLNPs have the function of actively targeting N3PSMACAR-T, the dasatinib hydrochloride-encapsulated DLNPs inhibited the action of N3 PSMACAR-T cells, and compared with the CAR-T group and CAR-T+Dasatinib DLNP group, the tumor growth in the N3 CAR-T+Dasatinib DLNP group was more obvious. And from Fig.11 It can be seen from B that after N3 PSMACAR-T uses dasatinib hydrochloride DLNP, the amount of cytokine IFN-γ in serum is significantly reduced, which can avoid the cytokine storm caused by excessive PSMACAR-T cell activity. The above experimental results show that the present invention has successfully prepared a nano-delivery system that uses bio-orthogonal in vivo targeted regulation of CAR-T cells. When the system uses dasatinib hydrochloride DLNP to target and regulate PSMACAR-T cells, it can avoid the cytokine storm caused by excessive PSMACAR-T cell activity.
[0102] Example 7 Collagenase IDLNP and N3 PSMACAR-T encapsulated in PSMA(+)PC3 tumor-bearing mice improve the tumor microenvironment and enhance the therapeutic effect of CAR-T
[0103] (B1) Preparation of collagenase-loaded IDLNPs
[0104] 50 mg of lecithin, 11 mg of cholesterol, 6.6 mg of DSPE-PEG2000 and 7.2 mg of DSPE-PEG2000-DBCO were dissolved in 3 mL of chloroform, vortexed to completely dissolve, and evaporated under reduced pressure using a vacuum rotary evaporator at 40°C to remove chloroform. After the organic phase formed a thin film at the bottom of the round-bottom flask, 3 mL of PBS solution dissolved with 2 mg / mL collagenase I was added, and stirred for 30 minutes under heating conditions at 37°C in a water bath; after the film was completely hydrated, the liposomes were treated with ultrasound using a probe in an ice bath for 5 minutes; a 30 kd ultrafiltration tube was used for ultrafiltration at a speed of 5000 r / min for 10 minutes, and ultrafiltration was performed three times to remove free drugs, and the upper layer of liquid was collected. The upper layer of liquid was extruded 10 times through a 100 nm filter membrane using an Avanti liposome extruder to finally obtain the product of collagenase IDLNP.
[0105] The particle size distribution is measured by Malvern particle size analyzer. Fig.12 As shown in A in the figure, its morphology was observed by transmission electron microscopy. Fig.12 As shown in B.
[0106] Fig.12 The results showed that the collagenase-loaded IDLNP prepared in this example was spherical with an average particle size of 132.8 nm.
[0107] (B2) Logarithmically growing PSMA(+) PC3 cells were obtained, digested with trypsin, and resuspended in culture medium to collect the cells. The cell density was adjusted with sterile phosphate buffered saline (PBS) for later use;
[0108] (B3) 6-8 week old male NSG mice were selected to establish PSMA(+) PC3 tumor-bearing mouse model. Each NSG mouse was subcutaneously injected with (B2) to obtain a concentration of 5×10 6 / mL PSMA(+) PC3 cell suspension 0.1mL;
[0109] (B4) PSMA CAR-T cells and N3 PSMA CAR-T cells were prepared according to the method of step (2) in Example 2. When the subcutaneous tumor of the tumor-bearing mouse model established in (B3) reached 50 mm 3 Afterwards, the mice were randomly divided into 4 groups, namely group 1, group 2, group 3, and group 4, which were respectively named control group, CAR-T group, CAR-T+Collagenase group, and N3 CAR-T+CollagenaseDLNP group. Group 1 was intravenously injected with 100 μL PBS solution; Group 2 was intravenously injected with 5×10 6 PSMACAR-T cells; 5×10 6PSMACAR-T cells were injected intratumorally twice with collagenase I 2 days and 4 days after PSMACAR-T injection. 5×10 6 N3 PSMA CAR-T cells were injected intravenously twice, 2 days and 4 days after N3 PSMA CAR-T injection.
[0110] (B4) The tumor size was measured every 2 days, and the mice were weighed. The tumor volume was obtained by measuring the length and width of the tumor with a vernier caliper. The mice were euthanized on day 18. The mouse tumors were taken and weighed, and then sliced. Immunohistochemistry was performed to detect the content of collagen in the tumor tissue and the infiltration of CD3+T cells in the tumor tissue.
[0111] from Fig.13 It can be seen that the tumors of the tumor-bearing mice in group 1 injected with PBS by the tail vein grew rapidly within 18 days; the tumor-bearing mice in group 2 injected with CAR-T by the tail vein had limited inhibitory effect on tumor growth; the intratumoral injection of collagenase I in group 3 enhanced the killing effect of CAR-T cells; the tumor-bearing mice in group 4 injected with N3 PSMACAR-T by the tail vein and treated with collagenase IDLNP, because the collagenase IDLNP was actively targeted to N3 PSMACAR-T cells, degraded the surrounding collagen, improved the immune microenvironment, enhanced the infiltration effect of T cells, and produced a strong tumor inhibition effect. The above experimental results illustrate that the present invention successfully prepared a nano-delivery system that uses bio-orthogonal in vivo targeted regulation of PSMACAR-T cells. When the system uses the collagenase IDLNP to target and regulate the tumor microenvironment of PSMACAR-T cells, it can improve the immune microenvironment and produce a strong tumor inhibition effect.
[0112] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A nano-delivery system for targeted regulation of CAR-T cells, characterized in that: The nano-delivery system is drug-loaded DLNPs and N3 CAR-T cells; The preparation method of the drug-loaded DLNP comprises the following steps: Dissolve lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO in an organic solvent, add a buffer solution containing a drug after the organic phase forms a thin film, heat and stir, and perform ultrasonic homogenization, and then ultrafilter and take the upper layer of liquid to obtain DLNPs loaded with the drug; the drug is a drug that regulates the activity of CAR-T cells or a drug that regulates the tumor microenvironment of CAR-T cells; The preparation method of N3 PSMACAR-T cells comprises the following steps: The activated T cells were transfected with a lentivirus containing a CAR vector and cultured to obtain CAR-T cells, and Ac4GalNAz was added for co-culture to obtain N3 CAR-T cells.
2. The nano delivery system according to claim 1, characterized in that The mass ratio of the lecithin, cholesterol, DSPE-PEG2000 and DSPE-PEG2000-DBCO is (45-55):(10-12):(6-7):(7-7.5).
3. The nano delivery system according to claim 1, characterized in that The drug for regulating the activity of CAR-T cells includes a drug for activating the activity of CAR-T cells or a drug for inhibiting the activity of CAR-T cells; the drug for regulating the tumor microenvironment of CAR-T cells is a drug for improving the tumor microenvironment of CAR-T cells.
4. The nano delivery system according to claim 3, characterized in that The drug for activating the activity of CAR-T cells includes IL15, the drug for inhibiting the activity of CAR-T cells includes dasatinib hydrochloride; and the drug for improving the tumor microenvironment of CAR-T cells is collagenase I.
5. The nano delivery system according to claim 1, characterized in that The organic solvent includes chloroform, and the buffer solution includes PBS solution.
6. The nano delivery system according to claim 1, characterized in that The preparation of the activated T cells comprises the following steps: Lymphocytes are obtained from the venous blood of healthy people, and anti-CD3 / CD28 magnetic beads are added to activate T cells.
7. The nano delivery system according to claim 1, characterized in that The concentration of Ac4GalNAz is 45-55 μM, and the co-culture time is 40-50 h.
8. The nano delivery system according to claim 1, characterized in that The CAR-T cells are PSMA CAR-T cells, and the lentivirus containing the CAR vector is Lenti-GFP / PSMA-CAR virus.
9. The nano delivery system according to claim 1, characterized in that The mass ratio of the lecithin to the drug is (45-55):(0.8-1.0).
10. Use of the nano delivery system according to any one of claims 1 to 9, characterized in that: The application is one or more of the following: (1) Application of the nano-delivery system in the preparation of drugs for treating tumors; (2) Application of the nano-delivery system in the preparation of targeted tumor therapy drugs; (3) Application of the nano-delivery system in the preparation of drugs for reducing cytokine storm caused by CAR-T cells.
Citation Information
Patent Citations
Biologically orthogonal targeted cytomembrane biomimetic nanoparticle and preparation method and application thereof
CN110101684A
T cell and nanoparticle connection method based on click chemistry
CN112980786A
Macrophage nanoparticle compound as well as preparation method and application thereof
CN115708883A
Chimeric antigen receptor (CAR) and application in treatment of tumors
CN116063575A
